USA flag logo/image

An Official Website of the United States Government

THE SPECIFIC AIMS OF THIS PROJECT ARE TWOFOLD.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
1399
Program Year/Program:
1984 / SBIR
Agency Tracking Number:
1399
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Hybridoma Sciences Inc.
4761 High Howell Road Suite D Atlanta, GA 30084
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1984
Title: THE SPECIFIC AIMS OF THIS PROJECT ARE TWOFOLD.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE SPECIFIC AIMS OF THIS PROJECT ARE TWOFOLD. A HAT-SENSITIVE, NON-IMMUNOGLOBULIN SECRETING HUMAN MYELOMA CELL LINE WILL BE DEVELOPED AND CHARACTERIZED FOR SPECIFIC APPLICATION TO HUMAN HYBRIDOMA PRODUCTION AND A TISSUE CULTURE MEDIUM WILL BE DEVELOPED (NOT REQUIRING CONDITIONED MEDIUM OR FETAL BOVINE SERUM) TO SUPPORT THE GROWTH OF THIS CELL LINE. BOTH ARE RECOMMENDED BY THE NCI'S DIVISION OF CANCER BIOLOGY AND DIAGNOSIS IN THE OMNIBUS SOLICITATION SINCE THEY WILL MAKE POSSIBLE THE USE OF HUMAN CELL-DERIVED MONOCLONAL ANTIBODIES FOR CANCER DIAGNOSIS AND THERAPY. MONOCLONAL ANTIBODIES PRODUCED BY THE HYBRIDOMA TECHNIQUE OF KOHLER AND MILSTEIN HAVE ALREADY BEEN SHOWN TO HAVE BOTH DIAGNOSTIC AND THERAPEUTIC APPLICATION. IN TUMOR MODELS, MONOCLONAL ANTIBODIES CONJUGATED TO RADIONUCLIDES, CYTOTOXIC DRUGS OR TOXINS, OR EVEN UNCONJUGATED HAVE DEMONSTRATED INHIBITION OF TUMOR GROWTH AND IN SOME CASES REGRESSION OF ESTABLISHED TUMORS. HOWEVER, DUE TO THE NON-AVAILABILITY OF A NON-SECRETORY, HAT-SENSITIVE IN VITRO ADAPTED HUMAN MYELOMA LINE FOR HUMAN-HUMAN FUSIONS, THE ANTIBODIES UTILIZED HAVE BEEN FOR THE MOST PART OF MOUSE ORIGIN. THE MULTIPLE INJECTION OF FOREIGN PROTEINS SUCH AS MOUSE ANTIBODIES MAY RESULT IN AN ANAPHYLAXIS, IMMUNE COMPLEX VASCULITIS, AND/OR THE PRODUCTION OF BLOCKING ANTIBODIES IN THE PATIENT. THESE PROBLEMS WOULD THEORETICALLY BE REDUCED OR ELIMINATED IN A HUMAN-HUMAN SYSTEM. DURING PHASE I OF THIS STUDY HAT-SENSITIVE MUTANTS WILL BE DEVELOPED FROM A CELL LINE, K737 (LOZZIO) WHICH WAS DERIVED FROM THE PLEURAL EFFUSION OF A PATIENT WITH MULTIPLE MYELOMA. THE K737 CELLS WILL UNDERGO B-AZAGUANINE TREATMENT IN SEMI-SOLID AGAR TO DEVELOP THE HAT-SENSITIVE HPRT DEFICIENT (HPRT) MUTANTS. DURING PHASE II THE HAT-SENSITIVE HPRT MUTANTS SELECTED FROM PHASE I WILL BE FURTHER CHARACTERIZED AS TO GROWTH PROPERTIES, MORPHOLOGY AND FUSION EFFICIENCY. THE CELL LINE WILL UNDERGO FURTHER MUTATION IN ORDER TO SELECT FOR A HAT-SENSITIVE, HPRT MUTANT THAT DOES NOT SECRETE IMMUNOGLOBULIN. IMMUNOGLOBULIN LEVELS WILL BE TESTED BY THE PI WHILE KARYOLOGY STUDIES WILL BE DONE BY DR. LOZZIO. ALSO, DURING PHASE I AND II, A TISSUE CULTURE MEDIUM BASED ON HYBRIDOMA SCIENCES' LOW SERUM MEDIUM (HSI-LOSM) WILL BE DEVELOPED TO GROW THE CELLS WITHOUT CONDITIONED MEDIUM AND FETAL BOVINE SERUM. THE MEDIUM WILL BE FURTHER TESTED AGAINST VARIOUS OTHER CELL LINES WITH PARTICULAR EMPHASIS ON SUPPORTING THE GROWTH OF ESTABLISHED HYBRIDOMAS OF BOTH HUMAN AND MOUSE ORIGIN. THIS MEDIUM WOULD ALLOW FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES IN CULTURE WITHOUT INTERFERENCE OF FETAL BOVINE SERUM PROTEINS.

Principal Investigator:

Paul j. price
DIRECTOR
0

Business Contact:

Small Business Information at Submission:

Hybridoma Sciences Inc.
4761 Hugh Howell Road Suite D Atlanta, GA 30084

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No